Sign up USA
Proactive Investors - Run By Investors For Investors

Tough market conditions in China and the Gulf States weigh as Smith & Nephew's 2016 profits miss forecasts

The FTSE 100-listed firm posted trading profits of US$1.020bn for 2016, down 7% from 2015’s US$1.099bn, on revenue 1% higher at US$4.67bn.
Knee x-ray
Analysts were expecting the company to report trading profits of US$1.04bn and revenues of US$4.69bn

Europe's biggest artificial hip and knee maker, Smith & Nephew PLC (LON:SN.) saw its 2016 trading profits miss forecasts weighed by tough market conditions in China and the Gulf States.

The FTSE 100-listed firm posted trading profits of US$1.020bn for the full-year to December 31, down 7% from 2015’s US$1.099bn, on revenues 1% higher at US$4.67bn.

Analysts were expecting the company to report trading profits of US$1.04bn and revenues of US$4.69bn.

Olivier Bohuon, Smith & Nephew’s chief executive officer, said: “Market conditions in China and the Gulf States together shaved more than a percentage point of growth off the group in 2016.”

But, he added: “ China returned to growth in the second half, as did the Emerging Markets as a whole,"

Smith & Nephew said it expected stronger revenue growth in 2017, with underlying revenues seen increasing by 3-4% and trading profit margin increasing by 20-70 points.

Bohuon added: "I am confident we now have the right structure and capability in place and are focused on improving execution across the group, with a clear set of actions underway.

“Beyond this, with our innovative products and deep customer relationships, we are well set to deliver a stronger performance generating higher revenue growth and a better trading profit margin in the future."

The firm plans to pay a final dividend of 18.5 US cents, taking its full-year dividend to 30.8 US cents, unchanged on the previous year.

In early trading, Smith & Nephew shares topped the FTSE 100 fallers list, down 4.4%, or 53p at 1,148p.

 -- Adds share price --



Register here to be notified of future SN. Company articles
View full SN. profile View Profile

Smith & Nephew PLC Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Picture of drugs
January 25 2017
Gross profit in the half year to December was up by 34%
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use